Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

被引:14
|
作者
Giambra, Vincenzo [1 ]
Piazzolla, Annarita Valeria [2 ]
Cocomazzi, Giovanna [2 ]
Squillante, Maria Maddalena [2 ]
De Santis, Elisabetta [1 ]
Totti, Beatrice [1 ]
Cavorsi, Chiara [2 ]
Giuliani, Francesco [3 ]
Serra, Nicola [4 ]
Mangia, Alessandra [2 ]
机构
[1] Fdn IRCCS Casa Sollievo Sofferenza, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy
[2] Fdn IRCCS Osped Casa Sollievo Sofferenza, Liver Unit, I-71013 San Giovanni Rotondo, Italy
[3] Fdn IRCCS Osped Casa Sollievo Sofferenza, ICT Innovat & Res Unit, I-71013 San Giovanni Rotondo, Italy
[4] Univ Federico II, Dept Publ Hlth, I-80138 Naples, Italy
关键词
liver cirrhosis; SARS-CoV-2; mRNA vaccine; MELD score; COVID-19; VACCINES; LIVER-DISEASE;
D O I
10.3390/vaccines10081281
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunoresponses of patients with LC after two or three doses of the mRNA Pfizer-BioNTech vaccine against SARS-CoV-2 and to investigate clinical features associated with non-response. Material and methods: 179 patients with LC of CTP class A in 93.3% and viral etiology in 70.1% of cases were longitudinally evaluated starting from the day before the first dose to 4 weeks after the booster dose. Their antibody responses were compared to those of healthcare workers without co-morbidities. In a subgroup of 40 patients, B- and T-cell responses were also compared to controls. Results: At d31, d90 and d180 after BNT162b2 vaccine, no detectable SARS-CoV-2 IgG response was observed in 5.9%, 3.9% and 7.2% of LC patients as compared to 0 controls (p < 0.03). A delay in B-cell and lack of prompt T-cell response compared to healthcare workers was also registered. A significant correlation between antibody titers and cellular response was observed. A MELD score > 8 was the only independent predictor of poor d31 response (p = 0.028). Conclusions: Our results suggest that cirrhotic patients have a slower and in <10% suboptimal immune response to SARS-CoV-2 vaccination. Rates of breakthrough infections were comparable between cirrhotics and controls. The booster dose was critical in inducing both humoral and cellular responses comparable to controls.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
    Melin, Jan
    Svensson, Maria K.
    Albinsson, Bo
    Winqvist, Ola
    Pauksens, Karlis
    [J]. BMC IMMUNOLOGY, 2021, 22 (01)
  • [2] Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
    Jan Melin
    Maria K. Svensson
    Bo Albinsson
    Ola Winqvist
    Karlis Pauksens
    [J]. BMC Immunology, 22
  • [3] Evaluation of the Effectiveness of BNT162b2 Primary Vaccination and Booster Dose to SARS-CoV-2 in Eliciting Stable Mucosal Immunity
    Lambiase, Alessandro
    Sacchetti, Marta
    Mallone, Fabiana
    Tirassa, Paola
    Greco, Antonio
    Angeloni, Antonio
    Polimeni, Antonella
    [J]. BIOMEDICINES, 2022, 10 (10)
  • [4] Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
    Gambim Fonseca, Marcela Helena
    Matias Dinelly Pinto, Ana Carolina
    Souza Silva, Maria Francilene
    Lima de Melo, Amanda Campelo
    Vasconcelos, Germana Silva
    dos Santos, Eduardo Ruback
    de Carvalho Araujo, Fernanda Montenegro
    Monteiro de Andrade, Luiz Odorico
    [J]. EMERGING INFECTIOUS DISEASES, 2022, 28 (06) : 1237 - 1240
  • [5] Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Briasoulis, Alexandros
    Gumeni, Sentiljana
    Malandrakis, Panagiotis
    Papanagnou, Eleni-Dimitra
    Migkou, Magdalini
    Kanellias, Nikolaos
    Kastritis, Efstathios
    Trougakos, Ioannis P.
    Dimopoulos, Meletios A.
    [J]. BLOOD, 2022, 139 (09) : 1409 - 1412
  • [6] Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
    Clara Udaondo
    Carmen Cámara
    Laura Miguel Berenguel
    Rosa Alcobendas Rueda
    Celia Muñoz Gómez
    Claudia Millán Longo
    Blanca Díaz – Delgado
    Iker Falces-Romero
    Mariana Díaz Almirón
    Jordi Ochando
    Ana Méndez – Echevarría
    Agustín Remesal Camba
    Cristina Calvo
    [J]. Pediatric Rheumatology, 20
  • [7] Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
    Udaondo, Clara
    Camara, Carmen
    Berenguel, Laura Miguel
    Rueda, Rosa Alcobendas
    Gomez, Celia Munoz
    Longo, Claudia Millan
    Diaz-Delgado, Blanca
    Falces-Romero, Iker
    Almiron, Mariana Diaz
    Ochando, Jordi
    Mendez-Echevarria, Ana
    Camba, Agustin Remesal
    Calvo, Cristina
    [J]. PEDIATRIC RHEUMATOLOGY, 2022, 20 (01)
  • [8] Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
    Puro, Vincenzo
    Castilletti, Concetta
    Agrati, Chiara
    Goletti, Delia
    Leone, Sara
    Agresta, Alessandro
    Cimini, Eleonora
    Tartaglia, Eleonora
    Casetti, Rita
    Colavita, Francesca
    Meschi, Silvia
    Matusali, Giulia
    Lapa, Daniele
    Najafi Fard, Saeid
    Aiello, Alessandra
    Farrone, Chiara
    Galli, Paola
    Capobianchi, Maria Rosaria
    Ippolito, Giuseppe
    [J]. VACCINES, 2021, 9 (06)
  • [9] A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals
    Blazhevska, Teodora Brnjarchevska
    Babacic, Haris
    Sibinovska, Olgica
    Dobrevski, Boban
    Kirijas, Meri
    Milanovski, Gorjan
    Arsov, Todor
    Petlichkovski, Aleksandar
    [J]. ALLERGY, 2022, 77 (01) : 296 - 298
  • [10] A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals
    Blazhevska, Teodora Brnjarchevska
    Sibinovska, Olgica
    Trajkov, Dejan
    Kirijas, Meri
    Arsov, Todor
    Milanovski, Gorjan
    Mladenovska, Olivija Efinska
    Dobrevski, Boban
    Stanchev, Dragica Bliznakovska
    Savevska, Tamara
    Iljoska, Stefani
    Petlichkovski, Aleksandar
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 306 - 306